Table 3.
Trial | Neoadjuvant Treatment | Treatment Duration | Primary Endpoint | Estimated Completion |
---|---|---|---|---|
Immunotherapy | ||||
Group A:_Nivolumab Group B: Nivolumab + Ipilimumab |
Neoadjuvant: 7 weeks Adjuvant: 6 months |
Pathologic complete response | 2020 | |
Nivolumab + HF 10 | 12 weeks | Pathologic complete response | 2022 | |
Pembrolizumab Procedure: Surgery Radiation: IMRT |
12 weeks | Disease free survival | 2025 | |
Pembrolizumab and high dose interferon alfa-2b (HDI) | 6–8 weeks | Adverse events | 2019 | |
Group A: Dabrafenib + Trametinib THEN Pembrolizumab Group B: Dabrafenib + Trametinib + Pembrolizumab Group C: Pembrolizumab ONLY |
Neoadjuvant: 6 weeks Adjuvant: 46 weeks |
Pathologic complete response | 2019 | |
Ipilimumab + Nivolumab | 6 weeks | Response rate Recurrence free survival | 2020 | |
Pembrolizumab | One dose | Number of adverse events | 2022 | |
Pembrolizumab | 9 weeks | Event-free survival | 2022 | |
Group A: VX15/2503 + Nivolumab + surgery Group B: VX15/2503 + Ipilimumab + surgery Group C: VX15/2503 + Nivolumab + Ipilimumab Group D: VX15/2503 + surgery |
Two doses | Extent of CD8 T-cell infiltration following treatment | 2031 | |
Targeted Therapy | ||||
Drug: Vemurafenib + Cobimentinib | 8 weeks | Resectability rate | 2022 | |
Drug: Dabrafenib + Trametinib | 8 weeks | Relapse-free survival | 2019 | |
Drug: Vemurafenib + Cobimentinib | 4 weeks | Resectability rate | 2019 | |
Group A: Atezolizumab + Vemurafenib + Cobimentinib Group B: Atezolizumab + Cobimentinib |
12 weeks | Pathologic complete response | 2023 | |
Group A: Dabrafenib + Trametinib THEN Pembrolizumab Group B: Dabrafenib + Trametinib + Pembrolizumab Group C: Pembrolizumab ONLY |
Neoadjuvant: 6 weeks Adjuvant: 46 weeks |
Pathological response rate Resectability rate |
2019 | |
Other Therapies | ||||
GM-CSF | 14 days | Th1/Th2 ratio | 2019 | |
Daromun | 4 weeks | Recurrence free survival | 2020 |